XML 86 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net income (loss) $ 4,700,000,000 $ 1,671,000,000 $ 104,000,000
Adjustments to reconcile net income (loss) to cash provided by operating activities      
Gain on sale of businesses (8,000,000) 0 0
Depreciation and amortization 1,011,000,000 894,000,000 844,000,000
Deferred and prepaid income taxes (4,301,000,000) (87,000,000) 245,000,000
Stock-based compensation expense 157,000,000 140,000,000 127,000,000
Intangible asset impairment charges 105,000,000 35,000,000 4,000,000
Net loss (gain) on investments and notes receivable 30,000,000 (155,000,000) 92,000,000
Contingent consideration expense (benefit) (35,000,000) (21,000,000) (80,000,000)
Payment of contingent consideration in excess of amount recognized at acquisition (6,000,000) (9,000,000) (14,000,000)
Inventory step-up amortization 46,000,000 6,000,000 10,000,000
Exchange (gain) loss 358,000,000 (11,000,000) 15,000,000
Other, net 63,000,000 8,000,000 13,000,000
Increase (decrease) in operating assets and liabilities, net of acquisitions:      
Trade accounts receivable (130,000,000) (110,000,000) (30,000,000)
Inventories (290,000,000) (83,000,000) (107,000,000)
Other assets 45,000,000 (172,000,000) (20,000,000)
Accounts payable and accrued expenses 111,000,000 (631,000,000) 195,000,000
Other liabilities (18,000,000) (1,164,000,000) 28,000,000
Cash provided by (used for) operating activities 1,836,000,000 310,000,000 1,426,000,000
Investing Activities      
Purchases of property, plant and equipment (461,000,000) (316,000,000) (319,000,000)
Proceeds on disposals of property, plant and equipment 7,000,000 14,000,000 0
Payments for acquisitions of businesses, net of cash acquired (4,382,000,000) (1,448,000,000) (560,000,000)
Proceeds from divestiture of certain businesses 90,000,000 0 0
Proceeds from royalty rights 52,000,000 0 0
Payments for settlements of hedge contracts (199,000,000) 0 0
Payments for investments and acquisitions of certain technologies (149,000,000) (172,000,000) (131,000,000)
Cash provided by (used for) investing activities (5,041,000,000) (1,921,000,000) (1,010,000,000)
Financing Activities      
Payment of contingent consideration and royalty rights previously established in purchase accounting (135,000,000) (19,000,000) (33,000,000)
Proceeds from royalty rights transfer 256,000,000 0 0
Proceeds from short-term borrowings, net of debt issuance costs 700,000,000 999,000,000 0
Net increase (decrease) in commercial paper (575,000,000) 21,000,000 1,183,000,000
Proceeds from borrowings on credit facilities 0 569,000,000 2,156,000,000
Payments on borrowings from credit facilities 0 (569,000,000) (2,216,000,000)
Payments on short-term borrowings (1,000,000,000) 0 0
Payments on long-term borrowings and debt extinguishment costs (3,560,000,000) (602,000,000) (1,000,000,000)
Proceeds from long-term borrowings, net of debt issuance costs 7,229,000,000 987,000,000 0
Cash used to net share settle employee equity awards (65,000,000) (56,000,000) (65,000,000)
Proceeds from issuances of shares of common stock 123,000,000 101,000,000 85,000,000
Cash provided by (used for) financing activities 2,973,000,000 1,432,000,000 110,000,000
Effect of foreign exchange rates on cash 10,000,000 (8,000,000) 4,000,000
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (222,000,000) (188,000,000) 530,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 829,000,000 1,017,000,000 487,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 607,000,000 829,000,000 1,017,000,000
Supplemental Information      
Cash (received) paid for income taxes, net 242,000,000 1,037,000,000  
Income Taxes Paid     (42,000,000)
Cash paid for interest 449,000,000 262,000,000 235,000,000
Fair value of contingent consideration recorded in purchase accounting 127,000,000 248,000,000 94,000,000
Cash and cash equivalents 217,000,000 146,000,000 188,000,000
Restricted cash and restricted cash equivalents included in Other current assets 346,000,000 655,000,000 803,000,000
Restricted cash equivalents included in Other long-term assets $ 43,000,000 $ 27,000,000 $ 26,000,000